Compare Stocks: CVKD, FNCH, EGRX, and KPTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVKD Cadrenal Therapeutics	$1.01 +1.3%	$1.35	$0.82 ▼ $14.35	$3.61M	1.93	193,901 shs	318,243 shs
EGRX Eagle Pharmaceuticals	$0.20 -77.4%	$0.77	$0.00 ▼ $1.80	$2.60M	0.83	7,635 shs	4,189 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
KPTI Karyopharm Therapeutics	$0.34 -20.4%	$1.60	$0.34 ▼ $10.99	$7.71M	1.04	1.06 million shs	1.41 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVKD Cadrenal Therapeutics	+14.28%	+0.71%	-8.53%	-57.57%	-92.87%
EGRX Eagle Pharmaceuticals	-8.76%	-8.76%	+448.67%	+48.74%	-41.00%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-36.63%
KPTI Karyopharm Therapeutics	-15.38%	-34.24%	-73.45%	-95.52%	-92.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVKD Cadrenal Therapeutics	$1.01 +1.3%	$1.35	$0.82 ▼ $14.35	$3.61M	1.93	193,901 shs	318,243 shs
EGRX Eagle Pharmaceuticals	$0.20 -77.4%	$0.77	$0.00 ▼ $1.80	$2.60M	0.83	7,635 shs	4,189 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
KPTI Karyopharm Therapeutics	$0.34 -20.4%	$1.60	$0.34 ▼ $10.99	$7.71M	1.04	1.06 million shs	1.41 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVKD Cadrenal Therapeutics	+14.28%	+0.71%	-8.53%	-57.57%	-92.87%
EGRX Eagle Pharmaceuticals	-8.76%	-8.76%	+448.67%	+48.74%	-41.00%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-36.63%
KPTI Karyopharm Therapeutics	-15.38%	-34.24%	-73.45%	-95.52%	-92.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	1,187.13% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	2.57	Moderate Buy	$11.50	3,282.35% Upside

Current Analyst Ratings Breakdown

Latest CVKD, FNCH, EGRX, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Negative
7/31/2026	KPTI Karyopharm Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$7.00
7/31/2026	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$3.00
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy ➝ Neutral	$13.00 ➝ $3.00
7/28/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$16.00
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.01	$0.50 per share	0.40	N/A	∞
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
KPTI Karyopharm Therapeutics	$146.07M	0.05	N/A	N/A	($16.00) per share	-0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.17	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
KPTI Karyopharm Therapeutics	-$196.04M	-$13.09	N/A	N/A	N/A	-153.28%	N/A	-145.18%	11/2/2026 (Estimated)

Latest CVKD, FNCH, EGRX, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CVKD Cadrenal Therapeutics	-$0.91	N/A	N/A	N/A	N/A	N/A
11/9/2026	N/A	EGRX Eagle Pharmaceuticals	$0.7330	N/A	N/A	N/A	$45.03 million	N/A
11/2/2026	Q3 2026	KPTI Karyopharm Therapeutics	-$1.16	N/A	N/A	N/A	$33.54 million	N/A
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A
8/13/2026	Q2 2026	KPTI Karyopharm Therapeutics	-$1.37	-$2.32	-$0.95	-$2.32	$32.19 million	$33.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	3.87	3.87
KPTI Karyopharm Therapeutics	N/A	0.79	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVKD Cadrenal Therapeutics	7.92%
EGRX Eagle Pharmaceuticals	85.36%
FNCH Finch Therapeutics Group	21.77%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
CVKD Cadrenal Therapeutics	14.59%
EGRX Eagle Pharmaceuticals	28.90%
FNCH Finch Therapeutics Group	44.90%
KPTI Karyopharm Therapeutics	1.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVKD Cadrenal Therapeutics	5	3.57 million	3.05 million	Not Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
KPTI Karyopharm Therapeutics	228	22.68 million	22.30 million	Optionable

CVKD, FNCH, EGRX, and KPTI Headlines

Recent News About These Companies

Karyopharm Therapeutics stock falls 13.72 percent as liquidity tightens

October 5, 2026 | ad-hoc-news.deA

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026 | prnewswire.com

Die Karyopharm-Aktie ringt mit Liquidität und Studienrisiken

September 29, 2026 | ad-hoc-news.deA

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

September 4, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)

September 3, 2026 | theglobeandmail.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | prnewswire.com

Karyopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

August 31, 2026 | finanznachrichten.de

Karyopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib

August 31, 2026 | rttnews.com

Karyopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock Up

August 31, 2026 | rttnews.com

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

August 31, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 27, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 25, 2026 | globenewswire.com

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

August 21, 2026 | finance.yahoo.com

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 20, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 18, 2026 | globenewswire.com

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

August 13, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 13, 2026 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, FNCH, EGRX, and KPTI Company Descriptions

Cadrenal Therapeutics NASDAQ:CVKD

$1.01 +0.01 (+1.30%)

As of 03:22 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Eagle Pharmaceuticals NASDAQ:EGRX

$0.20 -0.69 (-77.40%)

As of 02:59 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 10/13/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$0.34 -0.09 (-20.45%)

As of 03:21 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, FNCH, EGRX, and KPTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, FNCH, EGRX, and KPTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, FNCH, EGRX, and KPTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, FNCH, EGRX, and KPTI Company Descriptions

Cadrenal Therapeutics NASDAQ:CVKD

Eagle Pharmaceuticals NASDAQ:EGRX

Finch Therapeutics Group NASDAQ:FNCH

Karyopharm Therapeutics NASDAQ:KPTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, FNCH, EGRX, and KPTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, FNCH, EGRX, and KPTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, FNCH, EGRX, and KPTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, FNCH, EGRX, and KPTI Company Descriptions

Cadrenal Therapeutics NASDAQ:CVKD

Eagle Pharmaceuticals NASDAQ:EGRX

Finch Therapeutics Group NASDAQ:FNCH

Karyopharm Therapeutics NASDAQ:KPTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools